The antiretroviral treatment gap between adults and children persists. The potential benefits
from rollout of new paediatric DTG-based fixed-dose combination ART for first-line treatment …

Since HIV was identified as the etiological agent of AIDS, there have been significant
advances in antiretroviral therapy (ART) that has reduced morbidity/mortality. Still, the viral …

Background: Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy
(ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding …

Objective To describe the priors and decision thresholds in phase 2 and 3 RCTs evaluating
drug efficacy using Bayesian methods. Study Design and Setting A systematic review of …

Background We evaluated dolutegravir pharmacokinetics in infants with human
immunodeficiency virus (HIV) receiving dolutegravir twice daily (BID) with rifampicin-based …

Background Cohort studies in adults with HIV showed that dolutegravir was associated with
neuropsychiatric adverse events and sleep problems, yet data are scarce in children and …

Approximately 3.2 million children and adolescents globally living with human
immunodeficiency virus (HIV) require lifelong antiretroviral (ARV) treatment (ART) to prevent …

Case 1 was born at term to a mother taking tenofovir disoproxil/emtricitabine,
darunavir/ritonavir. Maternal HIV viral load (VL)< 50 copies/ml< 4weeks prior to delivery, the …

Abstract Treatment options for children living with HIV have historically been less effective,
less practical and more difficult to implement compared with those for adults, as the research …

Background Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART)
due to its high efficacy and favorable tolerability. However, limited data exist regarding the …